$PFE

$PFE - Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance…

$PFE PFIZER Q3 2026 EARNINGS - REV: $16.58B (EST $15.87B) - ADJ EPS: 87C (EST 73C) - SEES FY REV: $62.0B TO $64.0B (PREVIOUSLY $60.5B TO $62.5B) - SEE…

$PFE - Pfizer Appoints Cecile Guegan as Chief Financial Officer…

$PFE Pfizer: Appoints Cecile Guegan as CFO and Executive Vice President, Effective November 1 ? • Leadership: Guegan permanently assumes the CFO role…

$PFE - Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma…

$PFE - Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026…

$PFE - Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026…

$PFE - Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer…

$PFE Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer…

$PFE - Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026…

$PFE - Pfizer Declares Fourth-Quarter 2026 Dividend…

$PFE - Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo…

$PFE PFIZER'S LITFULO MEETS CO-PRIMARY ENDPOINTS IN VITILIGO…

$PFE Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study. The study met its primary endpoint, demonstrating a statistically…

$PFE - Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study…

$PFE - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference…

$PFE PFIZER AND BIONTECH RECEIVE U.S. FDA APPROVAL FOR XFG-ADAPTED COVID-19 VACCINE…